Tuesday, May 12, 2026  |  8:00–9:00 PM ET

Activity Description

Despite the availability of established therapies for chronic inflammatory demyelinating polyneuropathy (CIDP), many patients experience incomplete responses, treatment-related burden, or disease progression, underscoring persistent gaps in therapeutic decision-making. Overview of Historical Treatments: Limitations and Challenges is the third of five sessions in the series titled, CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes delivered through the Project ECHO® collaborative learning model that addresses the need for a critical reexamination of historical and current treatment approaches by reviewing their limitations, exploring emerging therapeutic options, and applying case-based discussions that integrate disease pathophysiology, diagnostic accuracy, and collaborative care strategies to optimize long-term outcomes.

This Project ECHO® series is built around de-identified cases submitted by participants, reflecting real diagnostic and management challenges from everyday neurology practice. Case should contain de-identified info and submitters are expected to present their case. Case presenters will receive an honorarium.

Learning Objective

  • Evaluate current and emerging treatment options, including limitations of standard therapies and appropriate integration of novel agents into practice

Speaker

 

Ariel Marks, MD 
(he/him)
Program Director
Neuromuscular Medicine Fellowship
Boston University Medical Center
Assistant Professor of Neurology
Boston University Chobanian and Avedisian School of Medicine
Boston, MA

 

Ariel Marks, MD is a practicing neurologist at Boston University Medical Center (BUMC) and an Assistant Professor of Neurology at Boston University Chobanian and Avedisian School of Medicine (BUCASM) in Boston, Massachusetts. Dr. Marks received his degree in medicine at Temple University School of Medicine in Philadelphia, Pennsylvania, and completed his neurology residency training at BUMC in Boston, Massachusetts. He completed a 1-year fellowship in neuromuscular medicine at Massachusetts General Hospital and Brigham and Women’s Hospital in Boston, Massachusetts before returning to BUMC as faculty. Dr. Marks’ passion is clinical excellence, including diagnosis and management of disorders of the nerves and muscles; electrodiagnostics with nerve conduction studies and electromyography (EMG); and diagnosis and management of functional neurological disorders. He is also deeply involved with medical education: he serves as the Program Director of the BUMC neuromuscular fellowship, Co-Director of the BUCASM second-year neurology module, Associate Clerkship Director of the BUCASM third-year neurology clerkship, and is the Director of the BUCASM fourth-year field-specific advisor program, mentoring dozens of medical students as they match into neurology residency.

Credit Information

Jointly Accredited Provider

In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians (ACCME)

Boston University Chobanian & Avedisian School of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

IPCE

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physician Assistants (AAPA)

Physician Assistants (AAPA): Boston University Chobanian & Avedisian School of Medicine, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

ABIM MOC

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting 1.0 ABIM MOC credit per ECHO session. By participating and claiming credit, you agree to BU sharing your information with ACCME PARS the data conduit to the ABIM.

Pharmacists (ACPE)

This application-based activity is approved for 1.0 contact hour of continuing pharmacy credit.

Nurses (ANCC)

This activity is designated for 1.0 contact hour.

Note to Nurse Practitioners: The content of this CNE activity pertains to Pharmacology.

Certificate of Participation

This activity was certified for a maximum of 1.0 AMA PRA Category 1 Credit™. This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education Credit for learning and change.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and mitigated any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

FACULTY PRESENTER

Dr. Marks reports the following financial relationships:

•  Speakers Bureau: argenx

FACULTY PLANNERS

Dr. Caplan reports no financial relationships to disclose.

Dr. Loriaux reports no financial relationships to disclose.

Maggie Naclerio reports the following financial relationships:

•  Advisory Board: 06/2023-present- Margaret Naclerio served on UCB, Inc. Nursing & Advanced Practice Provider Education Strategy Working Group Providing insight toward nursing and APP education material

The following individuals have no financial relationships to disclose:

Linda G. Baer, MSPH, CHCP (Planning Committee)

Alison Li, MPH (Planning Committee)

Mary Gleason, PhD, CHCP (Planning Committee)

Warren Beckman (Planning Committee)

Scott J. Hershman, MD, FACEHP, CHCP (Planning Committee)

Sandra Caballero, PharmD (Planning Committee)

Sharon Tordoff (Planning Committee)

Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships that faculty, planners, authors, and anyone who may be in control of content have with ineligible companies have been mitigated.

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. IN NO EVENT SHOULD INFORMATION IN THE MATERIALS REGARDING LAWS, REGULATIONS, OR LEGAL LIABILITY BE CONSIDERED LEGAL ADVICE OR USED AS A SUBSTITUTE FOR CONSULTING WITH AN ATTORNEY.

*All identified conflicts of interest have been mitigated.

Unlabeled Use Disclosure

Faculty of this CME/CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices. CME Outfitters, LLC, the faculty, planners, and reviewers do not endorse the use of any product outside of the FDA labeled indications. Medical professionals should not utilize the procedures, products, or diagnosis techniques discussed during this activity without evaluation of their patient for contraindications or dangers of use.


This activity is supported through an independent educational grant from argenx.